トップページ > グループ紹介 > 免疫療法開発分野(柏) > 業績

業績

2022年

  1. Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-Saito C. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma. Cancer Letters 537: 215690, 2022
  2. Yagi N, Suzuki T, Mizuno S, Kojima M, Kubo M, Sugimoto M, Kobayashi S, Gotohda N, Ishii G, Nakatasura T. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.  Cancer Science. 2022 Feb 28. doi: 10.1111/cas.15313. Online ahead of print.
  3. Chida K, Kawazoe A, Suzuki T, Kawazu M, Ueno T, Takenouchi K, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishim S, Kuwata T, Sakamoto N, Watanabe J, Mano H, Ikeda M, Shitara K, Endo I, Nakatsura T, Yoshino T. Transcriptomic profiling of MSI-H/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy. Clinical Cancer Research. 2022 Mar 7:clincanres.0041.2022. doi: 10.1158/1078-0432.CCR-22-0041. Online ahead of print.
  4. Charneau J, Suzuki T, Shimomura M, Fujinami N, Mishima Y, Hiranuka K, Watanabe N, Yamada T, Nakamura N, Nakatsura T. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Science. 2022 Feb 4. doi: 10.1111/cas.15291. Online ahead of print.
  5. Ikarashi D, Kitano S, Tsuyukubo T, Takenouchi K, Nakayama T, Onagi H, Sakaguchi A, Yamashita M, Mizugaki H, Maekawa S, Kato R, Kato Y, Sugai T, Nakatsura T, Obara W, Pretreatment tumor immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. Br J Cancer. 126(4):606-614.2022

2021年

  1. Shen S, Wu Q, Liu J, Wu L, Zhang R, Uemura Y, Yu X, Chen L, Liu T. Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211056505. doi: 10.1177/20587384211056505.
  2. Kudo-Saito C, Ogiwara Y, Imazeki H, Boku N, Uemura Y, Zhang R, Kawano-Nagatsuma A, Kojima M, Ochiai A. CD11b+DIP2A+LAG3+ cells facilitate immune dysfunction in colorectal cancer. Am J Cancer Res. 2021 Nov 15;11(11):5428-5439. eCollection 2021.
  3. Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, Minagawa A, Ishikawa A, Yano H, Ishi T, Ito R, Goto M, Takahashi R, Uemura Y, Hotta A, Kaneko S. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat. Biomed. Eng. 5: 429-440, 2021
  4. Sakaguchi A, Horimoto Y, Onagi H, Ikarashi D, Nakayama T, Nakatsura T, Shimizu H, Kojima K, Yao T, Matsumoto T, Ogura K, Kitano S. Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. 29;23(1):99.2021
  5. Ikarashi D, Okimoto T, Shukuya T, Onagi H, Hayashi T, Sara L Sinicropi-Yao, Joseph M Amann, Nakatsura T, Kitano S, David P Carbone, Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. JTO Clin Res Rep. 20;2(10):100230.2021
  6. Nosaka K, Suzuki S, Yoshikawa T, Shimomura M, Kitami K, Yoshida K, Yoshihara M, Kikkawa F, Nakatsura T, Kajiyama H, Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer, Anticancer Research. 41(10):4741-4751.2021
  7. Charneau J,Suzuki T, Shimomura M, Fujinami N, Nakatsura T. Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances, Journal of Hepatocellular Carcinoma, 8;1035–1054.2021
  8. Aoki H, Ueha S, Nakamura Y, Shichino S, Nakajima H, Shimomura M, Sato A,  Nakatsura T, Yoshino T, Matsushima K. Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade. Cancer Science. 112(8):2993-3004.2021
  9. Morisue R, Kojima M, Suzuki T, Nakatsura T, Ojima H, Watanabe R, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Ishii G, Gotohda N, Fujiwara T, Ochiai A. Sarcomatoid Hepatocellular Carcinoma is Distinct from Ordinary Hepatocellular Carcinoma: Clinicopathologic, Transcriptomic, and Immunologic Analyses. International Journal of Cancer. 149(3):546-560.2021
  10. Chida K, Kawazoe A, Kawazu M, Suzuki T, Nakamura Y, Nakatsura T, Kuwata T, Ueno T, Kuboki Y, Kotani D, Kojima T, Taniguchi H, Mano H, Ikeda M, Shitara K, Endo I, Yoshino T. A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/ dMMR gastrointestinal tumors. Clinical Cancer Research. 1;27(13):3714-3724.2021
  11. Aoki H, Ueha S, Shichino S, Ogiwara H, Shitara K, Shimomura M, Suzuki T, Nakatsura T, Yamashita M, Kitano S, Kuroda S, Wakabayashi M, Kurachi M, Ito S, Doi T, Matsushima K. Transient depletion of CD4+ cells induces drastic remodeling of the repertoire of T-cell receptors in gastrointestinal cancer. Cancer Immunology Research. 9(6) :624-636, 2021
  12. Mizuhashi S, Kubo Y, Fukushima S, Kanemaru H, Nakahara S, Miyasita A, Ishibashi T, Kuriyama H, Kimura T, Masuguchi S, Zhang R, Iwama T, Nakatsura T, Uemura Y, Senju S, Ihn H. Immune cell therapy against disseminated melanoma by utilizing induced pluripotent stem cell-derived myeloid cell lines producing interferon-beta or interleukin-15/interleukin-15 receptor alpha. Journal of Dermatological Science. 102(2):133-136.2021
  13. Zhang R, Liu T, Tsuchiya N, Mashima H, Kobayashi T, Nakatsura T, Ohdan H, Endo I, Senju S, Uemura Y.  Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. Journal of Immunology and Regenerative Medicine. 12: 100042, 2021
  14. Mashima H, Zhang R, Kobayashi T, Tsukamoto H, Liu T, Iwama T, Hagiya Y, Yamamoto M, Fukushima S, Okada S, Idiris A, Kaneko S, Nakatsura T, Ohdan H, Uemura Y, Improved safety of induced pluripotent stem cell-derived antigen presenting cellbased cancer immunotherapy. Molecular Therapy: Methods & Clinical Development. 21:171-179, 2021
  15. Kuriyama H, Fukushima 1 S, Kimura T, Kanemaru H, Miyashita A, Okada E, Kubo Y, Nakahara S, Tokuzumi A, Nishimura Y, Kajihara I, Makino K, Aoi J , Masuguchi S, Tsukamoto H, Inozume T, Zhang R, Nakatsura T, Uemura Y, Senju S, Ihn H, Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma. Int. J. Mol. Sci. 22(4):1958, 2021
  16. Ukai M, Yokoi A, Yoshida K, Suzuki S, Shibata K, Kikkawa F, Nakatsura T, Kajiyama H. Extracellular miRNAs as predictive biomarkers for glypican-3-derived peptide vaccine therapy response in ovarian clear cell carcinoma. Cancers (Basel). 13(3):550, 2021
  17. Kim Y, Kobayashi E, Suehara Y, Ito A, Kubota D, Tanzawa Y, Endo M, Nakatani F, Nakatsura T, Kawai A, Kaneko K, Kitano S. Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. Oncol Lett. 21(3):212. 2021
  18. Iriguchi S, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, Ueda T, Minagawa A, Mishima Y, Yanagawa N, Baba Y, Miyake Y, Nakayama K, Takiguchi M, Shinohara T, Nakatsura T, Yasukawa M, Kassai Y, Hayashi S, Kaneko S. A clinically applicable and scalable method to regenerate T-cell from iPSCs for off-the-shelf T-cell immunotherapy. Nature Communications. 12(1):430. 2021
  19. Oka M, Xu L, Suzuki T, Yoshikawa T, Sakamoto H, Uemura H, Yoshizawa AC, Suzuki Y, Nakatsura T, Ishihama Y, Suzuki A, Seki M. Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer. Genome Biology. 22(1):9, 2021
  20. Hayashi T, Kohsaka S, Takamochi K, Kishikawa S, Ikarashi D, Sano K, Hara K, Onagi H, Suehara Y, Takahashi F, Saito T, Nakatsura T, Kitano S, Suzuki K, Yao T. Histological Characteristics of Lung Adenocarcinoma with Uncommon Actionable Alterations: Special Emphasis on MET exon 14 Skipping Alterations, Histopathology, 78(7):987-999.2021

2020年

  1. Su Y, Yamazaki S, Morisue R, Suzuki J, Yoshikawa T, Nakatsura T, Tsuboi M, Ochiai A, Ishii G. Tumor-infiltrating T cells concurrently overexpress CD200R with immune checkpoints PD-1, CTLA-4 and TIM-3 in non-small cell lung cancer. Pathobiology, 1-10. 2020
  2. Mashima H, Zhang R, Kobayashi T, Hagiya Y, Tsukamoto H, Tianyi Liu T, Iwama T, Yamamoto Y, Lin C, Nakatsuka R, Mishima Y, Watanabe N, Yamada T, Senju S, Kaneko S, Idiris A, Nakatsura T, Ohdan H, and Uemura Y. Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. Oncoimmunology. 9(1):1814620. 2020
  3. Ikarashi D, Kitano S, Isshida K, Nakatsura T, Shimodate H, Tsuyukubo T, Tamura D, Kato R, Sugai T, Obara W. Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. Front Oncol. 24;10:564714.2020.
  4. Nakajima H, Nakatsura T. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. Immunological Medicine, 9:1-6, 2020
  5. Daiko H, Marafioti T, Fujiwara T, Shirakawa Y, Nakatsura T, Kato K, Puccio I, Hikichi T, Yoshimura S, Nakagawa T, Furukawa M, Stoeber K, Nagira M, Ide N, Kojima T. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunology, Immunotherapy. 69(11):2247-2257.2020
  6. Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3 positive hepatocellular carcinoma induces peptide specific CTLs and improves. Cancer Science. 111(8):2747-2759.2020
  7. Akazawa Y, Saito Y, Yoshikawa T, saito K, Nosaka K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T. Efficacy of immunotherapy targeting the neoantigen derived from EGFR T790M/C797S mutation in non-small cell lung cancer. Cancer Science.   111(8):2736-2746.2020
  8. Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S. Non-clinical efficacy, safety, and stable clinical cell processing of iPSC-derived anti-GPC3 CAR-expressing NK/ILC cells. Cancer Science. 111(5):1478-1490, 2020
  9. Kimura T, Fukushima S, Okada E, Kuriyama H, Kanemaru H, Kadohisa-Tsuruta M, Kubo Y, Nakahara S, Tokuzumi A, Kajihara I, Makino K, Miyashita A, Aoi J, Makino T, Tsukamoto H, Nishimura Y, Inozume T,Zhang R, Uemura Y, Senju S, Ihn H. Induced Pluripotent Stem Cell-Derived Myeloid Cells Expressing OX40 Ligand Amplify Antigen-Specific T Cells in Advanced Melanoma. Pigment Cell Melanoma Res. 33(5):744-755.2020
  10. Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, Yoshida T, Nakatsura T. Usefulness of plasma full-length GPC3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncology Letters. 19:2657-2666, 2020
  11. Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Science. 111(2):334-342, 2020
  12. Imaizumi K, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, Sasaki T, Nishizawa Y, Taketomi A, Ito M, Nakatsura T. Ki67 expression and localization of T-cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Science. 111(1):23-35, 2020

2019年

  1. Akazawa Y, Hosono A, Yoshikawa T, Kaneda H, Nitani C, Hara J, Kinoshita Y, Kohashi K, Manabe A, Fukutani M, Wakabayashi M, Sato A, Shoda K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: a phase I clinical trial. Cancer Science. 110(12):3650-3662, 2019
  2. Tsuchiya N, Zhang R, Iwama T, Ueda N, Liu T, Tatsumi M, Sasaki Y, Shimoda R, Osako Y, Sakaue-Sawano A, Sawada Y, Negishi H, Kimura Y, Kubo Y, Miyashita A, Fukushima S, Nakaki R, Takubo K, Okada S, Miyawaki A, Kaneko S, Ihn H, Taniguchi T, Kaisyo T, Nishimura Y, Senju S, Endo I, Nakatsura T, Uemura Y. Type I Interferon Delivery by iPSC-derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. Cell Reports, 29(1):162-175, 2019
  3. Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T. Heat shock protein 105 peptide vaccine could induce anti-tumor immune reactions in a phase I clinical trial. Cancer Science. 110(10):3049–3060, 2019
  4. Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. J Immunother Cancer. 7(1):195. 2019
  5. Zhang R, Kitayama S, Liu T, Ueda N, Tokumitsu Y, Mashima H, Ohdan H, Kaneko S, Uemura Y. In vitro detection of cellular adjuvant properties of human invariant natural killer T cells. Methods in Molecular Biology. 2048:121-130, 2019
  6. Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Frontiers in Oncology. 9:248, 2019
  7. Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. Scientific Reports. 9(1):5925, 2019
  8. Shimizu Y, Nakatsura T. Glypican-3: Hepatocellular carcinoma specific antigen, a novel target for cancer immunotherapy. Liver and Glycosylation. Glycoforum. Vol.22(1),2019
  9. Okada M, Tada Y, Seki T, Tohyama S, Fujita J, Suzuki T, Shimomura M, Ofuji K, Kishino Y, Nakajima K, Tanosaki S, Someya S, Kanazawa H, Senju S, Nakatsura T, Fukuda K. Selective limination of Undifferentiated Human Pluripotent Stem Cells Using Pluripotent State-Specific Immunogenic Antigen Glypican-3. Biochem. Biophys. Res. Comm. 511(3):711-717, 2019
  10. Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-Analysis. (review) 7(3);80-95, 2019
  11. Akazawa Y, Nobuoka D, Takahashi M, Yoshikawa T, Shimomura M, Yagi T, Fujiwara Y, Nakamoto Y, Nakatsura T. Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. Cancer Science. 110(6):1842-1852. 2019

2018年

  1. Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell. 23(6):850-858, 2018
  2. Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Sci Rep. 8(1):13166, 2018
  3. Cheng Z, Peng HL, Zhang R, Fu XM, Zhang GS. In vitro hematopoietic differentiation from pluripotent stem cells or by direct lineage conversion: current advances and challenges. Journal of medical and biological engineering. 38(2):186-196, 2018
  4. Shimizu Y, Suzuki T, Yoshikawa T, Tsuchiya N, Sawada Y, Endo I, Nakatsura T. Cancer Immunotherapy Targeted Glypican-3 or Neoantigens. Cancer Sci. 109(3):531-541, 2018
  5. Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S. Generation of TCR expressing innate lymphoid-like helper cells that induces cytotoxic T cell-mediated anti-leukemia cell response. Stem Cell Reports. 10:213-227, 2018.
  6. Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y. BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Cell Mol Immunol. 15(1):15-26. 2018
  7. Wu L, Liu H, Guo H, Wu Q, Yu S, Qin Y, Wang G, Wu Q, Zhang R, Wang L, Zhang L, Liu L, Jiao S, Liu T. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. Oncol Lett. 15: 9507-9515, 2018.

2017年

  1. Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, Wu L, Yu S, Shi F, Li Y, Zhang L, Wang L, Feng S, Zhang Q, Peng Y, Wu Q, Liu C, Chang X, Yang L, Uemura Y, Yu X, Liu T. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 411:182-190, 2017
  2. Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology. 6(10):e1346764, 2017
  3. Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Fujinami N, Saito K, Mizuno S, Nakatsura T. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. OncoImmunology.  7(1):e1377872, 2017
  4. Cheng Z, Peng HL, Zhang R, Fu XM, Zhang GS. Rejuvenation of Cardiac Tissue Developed from Reprogrammed Aged Somatic Cells. Rejuvenation Res. 20(5):389-400. 2017
  5. Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakwa H, Nobuoka D, Yawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget. 8(23): 37835-44, 2017
  6. Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q, Liu J, Liu T, Zhang Q. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temolomide in GBM cell lines. Neuroscience, 29;346:298-308, 2017
  7. Cheng Z, Peng HL, Zhang R, Fu XM, Zhang GS. Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis. Cell Immunol. 311:46-53, 2017

2016年

  1. Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, Kikkawa F, Nakatsura T. Efficacy of Glypican-3-derived Peptide Vaccine Therapy on the Survival of Patients with Refractory Ovarian Clear Cell Carcinoma. OncoImmunology. 5(11) ;e1238542, 2016
  2. Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T. Hepatocellular carcinoma cell sensitivity to Vg9Vd2 T lymphocyte-mediated killing is increased by zoledronate. Int. J. Oncol. 48: 1794-1804, 2016
  3. Kitayama S, Zhang R, Liu T-Y, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, Kaneko S. Cellular adjuvant properties and direct cytotoxicity of redifferentiated Va24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Reports. 6 (2): 213-227, 2016
  4. Nakatsuka R, Iwaki R, Matsuoka Y, Sumide K, Kawamura H, Fujioka T, Sasaki Y, Uemura Y, Asano H, Kwon A-H, Sonoda Y. Identification and characterization of Lineage-CD45-Sca-1+ VSEL phenotypic residing in adult mouse bone tissue. Stem Cells and Development. 25: 27-42, 2016.
  5. Fujinami N, Yoshikawa T, Sawada Y, Shimomura M, Iwama T, Sugai S, Kitano S, Uemura Y, Nakatsura T. Enhancement of antitumor effect by peptide vaccine therapy in combination withanti-CD4antibody: Study in a murine model. Biochemistry and Biophysics Reports. 5;482-491,2016
  6. Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology. 5(5); e1129483,2016
  7. Iwama T, Uchida T, Sawada Y, Tsuchiya N, Sugai S, Shimomura M, Yoshikawa T, Zhang R, Uemura Y, Nakatsura T. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochem. Biophys. Res. Comm. 469(1):138-43. 2016
  8. Mohammad A.S, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y. Identification of Glypican-3-Derived Long Peptides Activating both CD8+ and CD4+ T-cells; Prolonged Overall Survival in Cancer Patients with Th Cell Response. OncoImmunology. 2015 Aug 31;5(1):e1062209. eCollection 2016.

2015年

  1. Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma, World J Gastroenterol. 21(36):10314-10326,2015(review)
  2. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma, World J Gastroenterol. 21(37):10573-10583,2015(review)
  3. Sakamoto R, Rahman MM, Shimomura M, Itoh M, Nakatsura T. Time-Lapse Imaging Assay Using the Biostation CT: A Sensitive Drug-Screening Method for 3D Cell Culture. Cancer Sci. 106(6);757-765, 2015
  4. Zhang R, Liu T, Senju S, Haruta M, Hirosawa N, Suzuki M, Tatsumi M, Ueda N, Maki H, Nakatsuka R, Matsuoka Y, Sasaki Y, Tsuzuki S, Nakanishi H, Araki R, Abe M, Akatsuka Y, Sakamoto Y, Sonoda Y, Nishimura Y, Kuzushima K. Uemura Y. Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells. Cancer Immunol. Res. 3 (6): 668-677 2015
  5. Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y. Prospectively isolated human bone marrow-derived MSCs support primitive human CD34-negative hematopoietic stem cells. Stem Cells. 33 (5): 1554-1565, 2015
  6. Nakatsuka R, Matsuoka Y, Uemura Y, Sumide K, Iwaki R, Takahashi M, Fujioka T, Sasaki Y, Sonoda Y. Mouse dental pulp stem cells support human umbilical cord blood-derived hematopoietic stem/progenitor cells in vitro. Cell Transplantation. 24: 97-113, 2015
  7. Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T. A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer. Int. J. Oncol. 46:497-504,2015
  8. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46:28-36,2015

2014年

  1. Ofuji K, Saito K, Yoshikawa T, Nakatsura T. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2014 21;1:35-42. doi: 10.2147/JHC. S48517. eCollection 2014. (review)
  2. Yoshikawa T, Takahara M, Tomiyama M, Nieda M, Maekawa R, Nakatsura T. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. Int. J. Oncol. 45:1847-1856,2014
  3. Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K, Nakatsura T. Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. Oncol. Rep. 32:1772-1778,2014
  4. Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Identification of a novel HLA-A* 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncol. Rep. 32(1):33-39,2014
  5. Sawada Y, Komori H, Tsunoda Y, Shimomura M, Takahashi M, Baba H, Ito M, Saito N, Kuwano H, Endo I, Nishimura Y, Nakatsura T. Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncol. Rep. 31(3):1051-1058,2014
  6. Suzuki S, Shibata K, Kikkawa F, Nakatsura T. Significant Clinical Response of Progressive Recurrent Ovarian Clear Cell Carcinoma to Glypican-3-derived Peptide Vaccine Therapy: Two Case Reports. Hum Vacc Immunother. 10(2):338-343,2014

2013年

  1. Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M,Shirakawa H, Nobuoka D and Nakatsura T. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide. Int. J. Oncol. 43(4):1019-1026,2013
  2. Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case.  Hum Vacc Immunother. 9(6):1228-1233,2013
  3. Nobuoka D, Yoshikawa T, Fujiwara T, and Nakatsura T.  Peptide intra-tumor injection for cancer immunotherapy:Enhancement of tumor cell antigenicity is a novel and attractive strategy. Hum Vacc Immunother. 9(6):1234-1236,2013
  4. Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement of antigen-specific cancer immunotherapy. Cancer Immunol Immun. 62(4):639-652,2013
  5. Kondo S, Demachi-Okamura A, Hirosawa T, Maki H, Fujita M, Uemura Y, Akatsuka Y, Yamamoto E, Shibata K, Ino K, Kikkawa F, Kuzushima K. An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules. Hum Immunol. 74: 1103-1110, 2013
  6. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Gotoh H, Zhu D, Nakayama K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 12: 114-126, 2013
  7. Iwama T, Horie K, Yoshikawa T, Nobuoka D, Shimomura M, Sawada Y, Nakatsura T. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int. J. Oncol. 42(3):831-838,2013
  8. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T. Peptide vaccines for hepatocellular carcinoma. Hum Vacc Immunother. 9(1):210-212,2013

2012年

  1. Sawada Y, Sakai M, Yoshikawa T, Ofuji K , Nakatsura T. A glypican-3-derived peptide vaccine against hepatocellular carcinoma. OncoImmunology. 1(8):1448-1450,2012
  2. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagori T, Takahashi S, Gotoda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma : immunological evidence and potential for improving overall survival. Clin. Cancer Res. 18(13):3686-3696, 2012
  3. Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y, Kojima S, Kuzushima K. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. J. Immunother. 35: 598-606, 2012